≡

Recombinant Antibody to Programmed Cell Death Protein 1 (PD1)

CD279; PDCD1; SLEB2; HPD1P

  • Product No.RAA751Ca81
  • Organism SpeciesCanis familiaris; Canine (Dog) Same name, Different species.
  • SourceRecombinant monoclonal antibody preparation
  • Host293F
  • Potency (Clone Number)n/a
  • Ig Isotype IgG
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelFITC
  • Immunogen n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid
  • Concentration1mg/mL
  • Organism Species Moren/a
  • ApplicationsWB; IF; ICC; IHC; IP; FCM.
    If the antibody is used in flow cytometry, please check FCM antibodies.
  • Downloadn/a
  • UOM 20µl100µl 200µl 1ml 10ml
  • FOB US$ 186  US$ 434  US$ 620  US$ 1550  US$ 6200 
    For more details, please contact local distributors!

SPECIFITY

The antibody is a mouse monoclonal antibody raised against PD1. It has been selected for its ability to recognize PD1 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Oncotarget Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. pubmed:28545019
CyberLeninka Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке :
АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ …
International Journal of Molecular Sciences Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity Pubmed: 30699956
PLoS One Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … Pubmed: 30807610
Cancers Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544
Catalog No. Related products for research use of Canis familiaris; Canine (Dog) Organism species Applications (RESEARCH USE ONLY!)
EPA751Ca62 Eukaryotic Programmed Cell Death Protein 1 (PD1) Positive Control; Immunogen; SDS-PAGE; WB.
RPA751Ca01 Recombinant Programmed Cell Death Protein 1 (PD1) Positive Control; Immunogen; SDS-PAGE; WB.
RAA751Ca81 Recombinant Antibody to Programmed Cell Death Protein 1 (PD1) WB; IF; ICC; IHC; IP; FCM.